CHRNA7 and neoplasm: Our findings demonstrate that pharmacologic activation of CHRNA7 reduced tumor progression and improved survival, which led us to explore its effects across multiple models including the E0771 model, the highly aggressive and metastatic 4T1 TNBC model, and the spontaneous multifocal MMTV-PyMT model.